New hope for aggressive brain cancer: experimental therapy VRT106 enters human trials

NCT ID NCT07093814

Recruiting now Disease control Sponsor: Guangzhou Virotech Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug, VRT106, in 42 adults whose glioblastoma (a fast-growing brain tumor) has returned or worsened. The main goals are to check safety, find the best dose, and see if it helps shrink tumors or extend life. Participants receive VRT106 by injection and are closely monitored.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA

Contacts and locations

Locations

Guangxi Medical University Cancer Hospital
RECRUITING

Nanning, Guangxi, China
Nanfang Hospital, Southern Medical University
NOT_YET_RECRUITING

Guangzhou, Guangdong, China
Qilu Hospital of Shandong University
NOT_YET_RECRUITING

Jinan, Shandong, China
Sanbo Brain Hospital Capital Medical University
NOT_YET_RECRUITING

Beijing, Beijing Municipality, China
Shenzhen Second People's Hospital
RECRUITING

Shenzhen, Guangdong, China
Sun Yat-sen University Cancer Center
RECRUITING

Guangzhou, Guangdong, China
Tangdu Hospital of Air Force Medical University of the PLA
NOT_YET_RECRUITING

Xi’an, Shanxi, China
The Cancer Hospital Affiliated to Chongqing University
NOT_YET_RECRUITING

Chongqing, Chongqing Municipality, China
The Fifth Affiliated Hospital of Sun Yat-sen University
RECRUITING

Zhuhai, Guangdong, China
The First Affiliated Hospital of USTC
NOT_YET_RECRUITING

Hefei, Anhui, China
The Second Affiliated Hospital of Zhejiang University School of Medicine
RECRUITING

Hangzhou, Zhejiang, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.